TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02701270

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental Dietary Fibre 1
Description: 22.17 g of product diluted in 250 ml of water taken once orally.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental Dietary Fibre 2
Description: 21.84 g of product diluted in 250 ml of water taken once orally.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polydextrose
Description: 21.48 g of product diluted in 250 ml of water taken once orally.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose
Description: 23.89 g of dextrose diluted in 250 ml of water taken once orally.
Study: NCT04236323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Not used remifentanil infusion
Description: Remifentanil is not used during operation
Study: NCT02908048

Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples collected at varying intervals over a two to three year period.

Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples collected at varying intervals over a two to three year period.

Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples collected at varying intervals over a two to three year period.

Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples collected at varying intervals over a two to three year period.
Study: NCT01010776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Extended Release (ER)
Description: Paliperidone ER tablets in the flexible dose ranging from 3 to 12 mg will be administered orally once daily for 26 weeks of Main Phase and for additional 26 weeks of Extension Phase to participants who continued with Extension Phase. Dosage was adjusted as per the Investigator's discretion.
Study: NCT02240992

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PBSC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCs
Study: NCT02616055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tesevatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tesevatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tesevatinib
Study: NCT04286711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-paclitaxel, Apatinib, Camrelizumab
Description: Albumin-paclitaxel: ivgtt, 75 or 100 or 125mg /m2, d1, d8, Repeat the therapeutic schedule every 3 weeks; Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the same time each day); Camrelizumab：ivgtt, 200mg, given on the first day, Q3W;
Study: NCT00371397

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hatha Yoga Classes
Description: Iyengar yoga, the form of hatha yoga used in this study, emphasizes the use of props to help students achieve precise postures safely and comfortably according to their particular body types and needs. The yoga activity sessions were directed by four experienced yoga teachers following a script. The poses used were (in order) Supta Baddha Konasana (Reclining Bound Angle Pose), Adho Mukha Svanasana (Downward Facing Dog), Supported Uttanasana (Intense Forward Stretch), Parsvotanasana (Intense Side Stretch Pose), Prasarita Padottanansana (Wide-Legged Forward Bend), Janu Sirsasana (Head to Knee Pose), Bharadvajasana (Simple Seated Twist Pose), Viparita Karani (Restful Inversion), Supported Setu Bandha Sarvanagasana (Bridge Pose), and Savasana (Corpse Pose). Blood draws occurred during the last two minutes of Supta Baddha Konasana (pose held 10 minutes), Viparita Karani (10 minutes), and Savasana (15 minutes).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Movement Control
Description: Walking on a treadmill at .5 miles per hour was used to control for general physical movement/cardiovascular expenditure because it best approximated the heart rates during the restorative yoga session. To match the lower heart rate, women also rested supine on a bed for several minutes after walking, before and after getting their blood drawn.
Study: NCT03828916

Intervention type: OTHER
Group type: OTHER
Intervention: NuShield
Description: SOC surgery with the addition of NuShield
Study: NCT03929276

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-intensity laser therapy & exercises
Description: A total of 15 sessions of high-dose laser treatment- i Lux Laser (Mectronic Medicale, Italy)- (in the first phase, 8 Watt for the analgesic effect; in the second phase, 12 Watt in burst mode for the biostimulation effect; and finally in the third phase with 8 Watt) will be applied.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Shame laser & exercises
Description: Sham laser treatment (the same device to be used, 0 watts) will be given.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: exercise
Description: Therapeutic exercises All participants received 25-minutes of passive stretching, active assisted range of motion and codman pendicular exercises (10 repetitions, 3 sets, 3-minutes rest between sets) to the shoulder joint, supervised by the same physiotherapist five times a week for 3 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Therapeutic exercises All participants received 25-minutes of passive stretching, active assisted range of motion and codman pendicular exercises (10 repetitions, 3 sets, 3-minutes rest between sets) to the shoulder joint, supervised by the same physiotherapist five times a week for 3 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Therapeutic exercises All participants received 25-minutes of passive stretching, active assisted range of motion and codman pendicular exercises (10 repetitions, 3 sets, 3-minutes rest between sets) to the shoulder joint, supervised by the same physiotherapist five times a week for 3 weeks.
Study: NCT00855179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Red vine leaf extract (AS 195)
Description: Antistax film-coated tablet 360 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets identical to those containing Anstistax 360 mg
Study: NCT03343444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 12 weeks (Sofosbuvir 400mg/Ledipasvir 90mg)
Description: Single Tablet (Sofosbuvir 400mg/Ledipasvir 90mg) daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 12 weeks (Sofosbuvir 400mg/Ledipasvir 90mg)
Description: Single Tablet (Sofosbuvir 400mg/Ledipasvir 90mg) daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8 weeks (Sofosbuvir 400mg/Ledipasvir 90mg)
Description: Single Tablet (Sofosbuvir 400mg/Ledipasvir 90mg) daily for 8 weeks
Study: NCT01211938

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: single-fraction radiotherapy with concomitant 5FU and Hydrea
Description: single-fraction radiotherapy with concomitant 5FU and Hydrea

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hyperfractionated radiotherapy with concomitant Cetuximab
Description: hyperfractionated radiotherapy with concomitant Cetuximab
Study: NCT01036139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF2.649 (pitolisant)
Description: 1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BF2.649 (pitolisant)
Description: 1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
Study: NCT04084600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy Protocol
Description: Kinesiotherapy Protocol is an specific exercise based treatment designed to strengthening, gaining range of motion and stretching the muscles.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Kinesiotherapy Protocol
Description: Kinesiotherapy Protocol is an specific exercise based treatment designed to strengthening, gaining range of motion and stretching the muscles.
Study: NCT02240992

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCs
Study: NCT02183610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] BI 1356 as oral (p.o.) solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] BI 1356 solution for i.v. infusion
Study: NCT03510403

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nastent™
Description: Snorer and OSA patients (mild or moderate OSA) use the nasal airway stent for sleeping, each night for 1 month.
Study: NCT04005755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maxigesic® IV
Description: acetaminophen 1000 mg + ibuprofen 300 mg, 100 ml solution for infusion
Study: NCT03566316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan/Amlodipine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Study: NCT04338698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine Sulfate (200 mg orally thrice a day for 5 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine Sulfate (200 mg orally thrice a day for 5 days)
Study: NCT03358875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Intravenous injection (Anti-PD-1 monoclonal antibody)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenous injection (Antineoplastic, cytotoxic, taxane)
Study: NCT03367962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-Ara-G
Description: the \[18F\]F-AraG tracer will be administered as a single bolus injection of approximately 5 mCi into a hand or arm vein.
Study: NCT04338698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine Sulfate (200 mg orally thrice a day for 5 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine Sulfate (200 mg orally thrice a day for 5 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir (75 mg orally twice a day for 5 days)
Study: NCT04338698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir (75 mg orally twice a day for 5 days)
Study: NCT04084600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy Protocol
Description: Manual therapy protocol: is a manual treatment intended to the release of fascias and soft tissues.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Traditional Massage
Description: Traditional Massage is a gentle and superficial massage.
Study: NCT04224831

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Source of growth factors: autologous platelet-rich plasma (aPRP) + repetitive electromagnetic stimulation for iontophoresis
Description: Autologous platelet rich plasma is containing many types of growth factors (GFs) such as epithelial growth factor (EGF), fibroblast growth factor (FGF), transforming growth factor (TGF), nerve growth factor (NGF), platelet-derived growth factor (PDGF), and insulin-like growth factor (IGF).~Repetitive high frequency electromagnetic stimulation (rEMS) creates a stimulated focus in the tissue by increasing blood flow and platelets at the capillary level. Electromagnetic stimulation along with growth factors has shown synergetic effects toward enhanced epithelial integrity and neural functions. With the addition of possible iontophoresis effects in the rEMS, the passage of the various active molecules can be augmented at the tissue level thereby increasing the widespread effect of the GFs in the damaged choroidal and outer retinal microenvironment.
Study: NCT01866215

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: glucose
Description: isocaloric nutrition with glucose, cream and whey protein during the 24 hour following a glycogen/intramyocellular lipid depleting exercise
Study: NCT04338698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir (75 mg orally twice a day for 5 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin (500 mg orally once a day on day 1, followed by 250 mg orally daily on days 2-5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin (500 mg orally once a day on day 1, followed by 250 mg orally daily on days 2-5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin (500 mg orally once a day on day 1, followed by 250 mg orally daily on days 2-5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin (500 mg orally once a day on day 1, followed by 250 mg orally daily on days 2-5)
Study: NCT04451239

Intervention type: DRUG
Group type: OTHER
Intervention: topical steroids and cyclosporin-A
Description: All patient will be treated with Topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .
Study: NCT03768960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will receive 16 mg/kg of daratumumab as IV infusion QW in Cycles 1 and 2 (Days 1, 8, 15 and 22) and Q2W in Cycle 3 to 6 (Days 1 and 15).
Study: NCT00838578

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KRN330
Description: KRN330 will be dosed at 0.5 mg/kg weekly until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be dosed at 180 mg/m2 biweekly until disease progression.
Study: NCT03331003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low level light therapy
Description: iRestore low-level light therapy on androgenetic alopecia

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: non-LLLT wavelength group
Description: A LED light device is non-curative for the patients.
Study: NCT01422317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPA / DHA / Alpha-Tocopherol
Description: Two gelatine capsules of Omacor-R (Pronova AS, Oslo) twice a day, each containing 850-882 mg eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethylesters in the average ratio of EPA to DHA of 1:2. Alpha-Tocopherol (4 mg) was added to each capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPA / DHA / Alpha-Tocopherol
Description: Two gelatine capsules of Omacor-R (Pronova AS, Oslo) twice a day, each containing 850-882 mg eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethylesters in the average ratio of EPA to DHA of 1:2. Alpha-Tocopherol (4 mg) was added to each capsule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corn Oil / Alpha-Tocopherol (4 mg)
Description: Two gelatine capsules twice a day. Each capsule contains 1g Corn Oil and 4 mg Alpha-Tocopherol
Study: NCT00461162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet DSMP
Description: Internet Dyspnea Self-management Program (i-DSMP): Education and skills training for dyspnea management; an individualized tailored exercise plan; self-monitoring of exacerbation symptoms and exercise; and reinforcement/personalized feedback for self management. I-DSMP participants will receive their accessing the modules through the website and participating in weekly online group chat sessions with the research nurse and other participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-Face Dyspnea Self-management
Description: Face-to-Face Dyspnea Self-management Program (f-DSMP): Education and skills training for dyspnea management; an individualized tailored exercise plan; self-monitoring of exacerbation symptoms and exercise; and reinforcement/personalized feedback for self management. F-DMSP participants will attend face-to-face group education sessions. The f-DSMP participants will be provide with a hard copy of the education modules and will participate in six 1-hour group sessions for a period of 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: 6 Monthly general health education classes and biweekly telephone calls from a health educator.
Study: NCT04736420

Intervention type: DRUG
Intervention: Rivaroxaban
Description: Rivaroxaban dispensing claim is used as the exposure group

Intervention type: DRUG
Intervention: Warfarin
Description: Warfarin dispensing claim is used as the reference group
Study: NCT04352504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond
Description: Consume 1.5 oz. serving almonds (246 calories) daily for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pretzel
Description: Consume 2 oz. serving of pretzels (216 calories) daily for 12 weeks
Study: NCT04925830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback; haemoncephalography biofeedback
Description: Ten 25-minute weekly heart rate variability biofeedback and 30 minute haemoencephalogrphy biofeedback sessions
Study: NCT01908855

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms
Description: Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms:~20 weekly sessions individual therapy (à 50) minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy for patients with multiple somatoform symptoms
Description: Cognitive-behavioral therapy for patients with multiple somatoform symptoms:~20 weekly sessions individual therapy (à 50) minutes
Study: NCT03991936

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Normal saline intralesional injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide 2.5 mg/mL
Description: 2.5 mg/mL intralesional injection
Study: NCT00616798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: 10mg po daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: 30mg po daily
Study: NCT00277810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lecozotan SR (SRA-333)
Description: one of 3 doses of lecozotan sr dose for 6 months as an extension to a 6 month study with patients required to be on a cholinesterase inhibitor 2, 5, or 10 mg of lecozotan sr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lecozotan SR (SRA-333)
Description: one of 3 doses of lecozotan sr dose for 6 months as an extension to a 6 month study with patients required to be on a cholinesterase inhibitor 2, 5, or 10 mg of lecozotan sr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lecozotan SR (SRA-333)
Description: one of 3 doses of lecozotan sr dose for 6 months as an extension to a 6 month study with patients required to be on a cholinesterase inhibitor 2, 5, or 10 mg of lecozotan sr
Study: NCT00616798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: 60mg po daily
Study: NCT00727545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iron bisglycine chelate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT03461549

Intervention type: DEVICE
Intervention: Pressure and Temperature Sensor
Description: This device includes pressure and temperature sensor embedded within silicone and applied to the skin with a medical grade adhesive.

Intervention type: DEVICE
Intervention: Pressure and Temperature Sensor
Description: This device includes pressure and temperature sensor embedded within silicone and applied to the skin with a medical grade adhesive.
Study: NCT00616798

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard antipsychotic therapy
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard antipsychotic therapy
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard antipsychotic therapy
Description: As prescribed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard antipsychotic therapy
Description: As prescribed
Study: NCT02001220

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Once daily screening
Description: In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily.~The initial SBT will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP \< to 5 cm H2 O or PS \< 8 cm H2 O with PEEP \< 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will choose one technique to be used for all patients enrolled at their centre.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: At least twice daily screening
Description: In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. Initial SBT will be conducted in the same manner as once daily screening arm. Subsequent SBTs will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP \< to 5 cm H2 O or PS \< 8 cm H2 O with PEEP \< 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O). Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will be asked to choose one technique to be used for all patients enrolled at their centre.
Study: NCT00372151

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Theanine
Description: 400 mg/day, caps.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: caps.
Study: NCT03887494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation
Description: Implantation of Y-Strut + cementoplasty in the femoral neck
Study: NCT05119348

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STOPCOV
Description: Fieldworkers delivered an infection mitigation intervention which consisted of personal protective equipment and messaging on managing COVID19 and reducing onward transmission of SARS-CoV-2 infection.
Study: NCT03466255

Intervention type: OTHER
Intervention: Ultrasound
Description: Contrast-enhanced ultrasound (CEUS)
Study: NCT03874286

Intervention type: DIAGNOSTIC_TEST
Intervention: Liver Transplant
Description: Patients will obtain a research blood draw and a liver biopsy at 4 months and 12 months post transplant. Liver biopsies are routinely performed in the liver transplant population. We will be obtaining a liver biopsy at this particular time point to compare the biopsy results with the peripheral blood results.